Two new studies from MIT and Harvard Medical School, focusing on a cytokine called IL-17, now add to that evidence. The researchers found that IL-17 acts on two distinct brain regions—the amygdala and ...

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

When we get sick, we often feel tired, moody, or anxious. Scientists have long known that this isn’t just about feeling ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

The interleukin-17 (IL-17) family cytokines are strong inducers of inflammation and help to protect us against invading pathogens. However, they also have a dark side and contribute to the tissue ...

In a 2019 study in mice, Choi and Huh showed that in some cases of infection, IL-17 is released and suppresses a small region of the brain's cortex known as S1DZ. Overactivation of neurons in this ...